A tumor’s molecular features, such as Programmed Death-Ligand 1 (PD-L1) expression or tumor mutational burden (TMB), are associated with positive response to ICIs and remain the most prominent biomarkers [1,2,3,4]. Here, CD274 is linked to neoplasm.